Pure Global

Triggering Oocyte Maturation in Normoresponders Using Double Trigger or HCG Trigger - Trial NCT06146413

Access comprehensive clinical trial information for NCT06146413 through Pure Global AI's free database. This Phase 2 trial is sponsored by Bedaya Hospital and is currently Not yet recruiting. The study focuses on Infertility. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06146413
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06146413
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Triggering Oocyte Maturation in Normoresponders Using Double Trigger or HCG Trigger
Triggering Oocyte Maturation in Normoresponders Using Double Trigger or HCG Trigger . A Randomized Controlled Trial

Study Focus

Infertility

Double trigger

Interventional

drug

Sponsor & Location

Bedaya Hospital

Giza, Egypt

Timeline & Enrollment

Phase 2

Dec 30, 2023

Dec 30, 2025

150 participants

Primary Outcome

Metaphase-II oocytes rate

Summary

The aim of this study is to compare the efficacy double trigger [ co-administration of GnRH
 agonist with HCG 40 and 34 h prior to ovum pick-up, respectively] with HCG trigger in
 inducing oocyte maturation.

ICD-10 Classifications

Female infertility
Male infertility
Female infertility, unspecified
Female infertility of other origin
Female infertility of uterine origin

Data Source

ClinicalTrials.gov

NCT06146413

Non-Device Trial